199 related articles for article (PubMed ID: 33751546)
21. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
[TBL] [Abstract][Full Text] [Related]
22. The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Rentsch P; Egan T; Kuriakose A; Stayte S; Vissel B
J Neurochem; 2023 Dec; 167(5):633-647. PubMed ID: 37916541
[TBL] [Abstract][Full Text] [Related]
23. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
[TBL] [Abstract][Full Text] [Related]
25. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
26. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Chotibut T; Meadows S; Kasanga EA; McInnis T; Cantu MA; Bishop C; Salvatore MF
Mov Disord; 2017 Nov; 32(11):1547-1556. PubMed ID: 28631864
[TBL] [Abstract][Full Text] [Related]
27. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
González-Aparicio R; Moratalla R
Neurobiol Dis; 2014 Feb; 62():416-25. PubMed ID: 24140894
[TBL] [Abstract][Full Text] [Related]
28. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
29. Dynamic Involvement of Striatal NG2-glia in L-DOPA Induced Dyskinesia in Parkinsonian Rats: Effects of Doxycycline.
Nascimento GC; Bortolanza M; Bribian A; Leal-Luiz GC; Raisman-Vozari R; López-Mascaraque L; Del-Bel E
ASN Neuro; 2023; 15():17590914231155976. PubMed ID: 37017068
[TBL] [Abstract][Full Text] [Related]
30. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Barnum CJ; Bhide N; Lindenbach D; Surrena MA; Goldenberg AA; Tignor S; Klioueva A; Walters H; Bishop C
Pharmacol Biochem Behav; 2012 Jan; 100(3):607-15. PubMed ID: 21978941
[TBL] [Abstract][Full Text] [Related]
31. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
32. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
33. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
34. 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.
Dos Santos Pereira M; Dias de Abreu GH; Vanderlei LCA; Raisman-Vozari R; Guimarães FS; Lu HC; Michel PP; Del Bel E
Neuropharmacology; 2024 Jun; 251():109926. PubMed ID: 38554815
[TBL] [Abstract][Full Text] [Related]
35. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
36. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
37. ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
Yuan Y; Zhang X; Wu Y; Lian P; Cao X; Xu Y
Neuroscience; 2023 Jul; 523():61-79. PubMed ID: 36796751
[TBL] [Abstract][Full Text] [Related]
38. l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
Klietz M; Keber U; Carlsson T; Chiu WH; Höglinger GU; Weihe E; Schäfer MK; Depboylu C
Neuroscience; 2016 Sep; 331():120-33. PubMed ID: 27320210
[TBL] [Abstract][Full Text] [Related]
39. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Lundblad M; Vaudano E; Cenci MA
J Neurochem; 2003 Mar; 84(6):1398-410. PubMed ID: 12614340
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Bastide MF; de la Crompe B; Doudnikoff E; Fernagut PO; Gross CE; Mallet N; Boraud T; Bézard E
Biol Psychiatry; 2016 Mar; 79(5):345-353. PubMed ID: 25442003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
